secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001493152-25-024061
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity Q2 FY2026 revenue up 19% to $3.9M; net loss narrows 53% to $0.77M
----------------------------------------------------------------------------

- Revenue $3.9M (+19% YoY); gross margin 81.9% vs 75.3% prior year.
- Net loss $0.77M ($0.03/sh) vs $1.7M ($0.07/sh), a 53% improvement.
- Recurring TaaS technology fees $3.5M, 88.7% of total revenue.
- Regulatory progress in Canada, Saudi Arabia, and Argentina; GPOs covering 90% of U.S. hospitals.
- CEO cites AI-driven automation and Biocore Pro adoption as growth drivers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315225024061/0001493152-25-024061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315225024061/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer